Following completion of the mergers, Nycomed Amersham and its two businesses, Nycomed Amersham Imaging and Amersham Pharmacia Biotech, further refine the strategy for enabling molecular medicine. The ultimate goal is to enable personalised medicine - providing predictive diagnostic and screening products along with gene-based therapies, tailored to the individual patient's genetic profile.

In 2001, the company and its businesses take new names and new identities, which more accurately describe their business and aspirations.